The Min (multiple intestinal neoplasia) strain of the laboratory mouse and its derivatives permit the fundamental study of factors that regulate the transition between normal and neoplastic growth. A gene of central importance in mediating these alternative patterns of growth is Apc, the mouse homologue of the human adenomatous polyposis coli (APC) gene. When adenomas form in the Min mouse, both copies of the Apc gene must be inactivated. One copy is mutated by the nonsense Apc allele carried in heterozygous form in this strain. The other copy can be silenced by any of several mechanisms. These range from loss of the homologue bearing the wild-type Apc allele; to interstitial deletions surrounding the wild-type allele; to intragenic mutation, including nonsense alleles; and ¢nally, to a reduction in expression of the locus, perhaps owing to mutation in a regulatory locus. Each of these proposed mechanisms may constitute a two-hit genetic process as initially posited by Knudson; however, apparently the two hits could involve either a single locus or two loci. The kinetic order for the transition to adenoma may be still higher than two, if polyclonal adenomas require stronger interactions than passive fusion.
INTRODUCTION
As a dynamically self-renewing tissue, the intestinal epithelium must maintain homeostasis by possessing both positive regulators driving cell proliferation and negative regulators mediating cell loss. The complexity of homeostatic regulation can be inferred from the fact that neoplasms of the intestinal epithelium, although among the most common of human cancers (Cutler et al. 1974) , do not a¥ict every individual in spite of the risk attendant to vast numbers of mitotic events per day within the intestinal epithelium. Indeed, the age dependence for the onset of clinically diagnosed colon cancer has been modelled mathematically as re£ecting a six-hit process (Peto et al. 1975) .
Descriptive analysis introduces members of the molecular and cellular casts of characters found in three biological dramas: normal, self-renewing growth; neoplastic growth; and regenerative growth after damage from ionizing radiation. Some of these characters can be shown to act as causative protagonists or antagonists within one or more of these dramas. A causative role is inferred by the discovery of a mutation a¡ecting the molecular or cellular character and simultaneously a¡ecting the biological process. The genes for which such mutational evidence has been available involve human families with strong predispositions to cancer. These highly penetrant, dominant mutations have enabled the molecular cloning of the causative molecules by analysis of DNA samples from a¡ected and una¡ected members of these families. However, the full dramas of normal selfrenewing growth and its deranged neoplastic counterpart involve far more than the highly penetrant protagonists and antagonists. How can investigators identify more fully the set of molecular and cellular interactions that can in£uence the outcome of the play? And once any one interaction has been identi¢ed on an abstract, formal basis, how can one analyse its mechanics?
These questions can best be addressed in an experimental organism, preferably a mammal. The laboratory mouse has been highly developed for controlled studies of cancer genetics and cancer biology. The production of genetic models for familial human cancers has not been routinely successful (Jacks 1996) . However, the Min (multiple intestinal neoplasia) mouse strain, heterozygous for a nonsense mutation in the mouse adenomatous polyposis coli (Apc) gene (Su et al. 1992) , does show at least the early stages of the familial cancer syndrome (Moser et al. 1990) . A number of investigators are studying how well the Min mouse can provide an experimental stage on which to identify functional interactions in the normal and neoplastic growth of the intestinal epithelium (see Dove et al. 1995; Shoemaker et al. 1997a) . The biology and genetics of the laboratory mouse is used in these studies to analyse in vivo the mechanism of interaction, through classical genetic pathway analysis and several modes of chimerism and mosaicism. It remains to be seen how accurately these in vivo analyses can be carried over to in vitro culture.
The ¢nal goal of the investigators working with the Min mouse strain is to determine whether mechanisms found to be important for the intestinal epithelium and its neoplasms in the laboratory mouse are also relevant to the human. No one presumes identity either in the biology or the genetic epidemiology between the mouse and the human species. But all must respect the depth of understanding that can be created by controlled experimentation. Given this starting point, it is necessary to make an appropriate interspecies translation from mouse to human.
THE CENTRALITY OF THE Apc REGULATOR
It is useful to view the`tumour suppressor gene' Apc as a regulator rather than an engine of cell behaviour: tumour cells and trophoblastic giant cells within embryos can thrive in the absence of Apc function. Several cell processes are known to be directly or indirectly regulated by Apc. These include transcription, adherens junction formation, the microtubular cytoskeleton, calcium-dependent cell adhesion, and cell migration (see Polakis 1995) .
As expected for a negative regulator, intestinal tumour formation commonly requires the loss of function of both alleles at the Apc locus (Knudson 1971; Luongo et al. 1994) (¢gure 1). For the Apc Min /+ mouse on the tumour-sensitive C57BL/6 genetic background, this process is completed by loss of the chromosome carrying the wild-type Apc allele. Interstitial deletions induced by somatic gamma irradiation delimit the necessary region of genetic loss to the Apc locus . Somatic treatment with ethylnitrosourea (ENU) induces point mutations in Apc, most frequently detected as chain terminations of the Apc polypeptide (Shoemaker et al. 1997b) .
When the Min mutation is placed on the highly tumourresistant AKR genetic background, the chromosomal loss pathway for removing wild-type Apc function is less prevalent (A. R. Shoemaker, unpublished data). Interestingly, F1 hybrids between the sensitive C57BL/6 strain and the resistant AKR strain show the chromosomal Apcloss pattern of C57BL/6 . This observation is consistent with dominant determination of chromosomal instability by an allele or alleles carried by C57BL/6 (see Lengauer et al. 1997) . Evidence for germline factors in£uencing karyotypic stability has now been published (Cahill et al. 1998) .
When the chromosome loss pathway is less frequent, as with strain AKRÁMin, a new scenario comes to light (¢gure 2). Tumours form at very low multiplicity, owing not only to the attenuation of the chromosome loss pathway but also to the action of resistance alleles of polymorphic modi¢er loci such as Mom1 (to be discussed below). When tumours form while retaining the chromosome carrying the wild-type Apc allele, the expression of the Apc polypeptide is attenuated (¢gure 3). This loss of expression is not accompanied by any known mutation of the Apc gene: the wild-type DNA sequence at the Min site is retained, and no chain-terminating mutations of Apc are detected (A. R. Shoemaker, unpublished data scenario is currently mysterious, with several conceivable explanations: (i) the wild-type allele might be silenced by a stable epigenetic change, along lines initially suggested by Solomon, Bodmer and their colleagues (Solomon et al. 1987) ; (ii) a speci¢c epigenetic mechanism, hypermethylation of the Apc promoter, might attenuate Apc expression (Hiltunen et al. 1997) ; or (iii) a second locus that regulates the expression of Apc might be somatically mutated (Haber et al. 1990) . Consistent with this last possibility, the incidence of tumours retaining but not expressing an apparently normal Apc allele is increased by appropriately timed ENU treatment of AKRÁMin mice (A. R. Shoemaker, unpublished data).
Note that adenoma formation by this alternative pathway remains dependent on the germline Apc Min allele: no intestinal adenomas have been found in control AKR animals. Evidently, the mechanism of attenuation, whether purely epigenetic (model (i) or (ii)) or downstream of a regulatory mutation (model (iii)), is not su¤ciently strong to silence successfully both wild-type copies of Apc in an Apc +/+ animal. The presentation of an alternative molecular genetic route to Min-dependent adenoma formation in strain AKR raises the possibility that there can be more than one stem cell origin for such tumours. The study of this possibility would be greatly enhanced if a rich set of diagnostic molecular markers became available for the stem cells of the intestinal epithelium and its neoplasms. At present, only the lacZ insertion ROSA11 provides such a marker .
Altogether, one feature is shared by the several speci¢c mechanisms of adenoma formation in the Min mouse:
Apc function must be strongly reduced or lost. This function must play a central role in protecting the normal intestinal epithelium against the dysplastic and neoplastic derangements that lead to adenoma and beyond. A central protective function such as this has been designated à gatekeeper' by Kinzler & Vogelstein (1996) . If Apc acts as a`gatekeeper', is loss of its function su¤cient to generate the intestinal adenoma?
The issue of su¤ciency is being pursued along three lines of inquiry: the search for developmental stages at which adenoma formation is enhanced; the analysis of cellular interactions between Apc-negative clones in adenoma formation; and the identi¢cation of loci other than Apc in which mutations enhance or suppress the probability of Min-induced adenoma formation. The developmental pro¢le for adenoma formation was studied by timed somatic treatment of Min mice with ENU. It was found that neonates up to 14 days of age were particularly susceptible to stimulation of adenoma formation .
THE POLYCLONAL STRUCTURE OF EARLY ADENOMAS IN Min MICE
The number of genetic events involved in tumorigenesis is increased if tumours are polyclonal (Novelli et al. 1996) . Whether this increase is obligatory depends upon whether the polyclonality is necessary. This issue requires deeper experimental study and has been started by analysing the clonal structure of early adenomas in the Min mouse (Merritt et al. 1997) . The analysis has employed a cell lineage marker, ROSA26, that expresses the b-galactosidase of E. coli in all cell types of the intestinal epithelium or its neoplasms (Wong et al. 1996; Zambrowicz et al. 1997; . Wholemount tissue stained with the substrate X-Gal can be visualized as blue before or after sectioning. To avoid complications of genetic modi¢ers of the tumour phenotype, ROSA26 was introgressed onto the standard sensitive genetic background, C57BL/6. Perhaps owing to the isogenicity of the two components of the aggregation chimeras, the intestinal epithelium shows very ¢ne-grained chimerism for the two participating genetic lineages (¢gure 4). The average patch diameter is only six crypts. By fusion of morulae emerging from appropriate crosses, two informative chimeric animals were generated, each with the composition ROSA26/+ Min/+ 6 +/+ Min/+.
Analysing tumours from these chimeras, Ch112 and Ch113, established that both the white and blue components carried the Min allele.
Each chimera was asymmetric, with a minority ROSA26/ + (blue) component. The best estimator of the proportion of adenomas that are polyclonal in structure can be made from this minority component, as the probability that a polyclonal tumour will be covert (blue Âblue) is small. Of a total of 260 adenomas from the entire intestinal tracts of the two informative chimeras, 28 adenomas were observed with at least some blue contribution. Of these, 22 were mixed with white tumour tissue.Thus, the proportion of polyclonal adenomas can be estimated to be at least 79%.
These observations are consistent with the study of polyclonality in a human familial adenomatous polyposis (FAP) patient reported by Novelli et al. (1996) . Importantly, the chimeric analysis that is permitted by the ROSA26 cell lineage marker is not open to the alternative interpretation o¡ered by Novelli and his colleagues for their material: that the mixed XY/XO karyotype of the human FAP adenomas had been created after the initiation of the tumour by loss of the dicentric Y chromosome within the tumour. However, neither set of observations demonstrates that the adenoma is polyclonal when ¢rst formed. Alternative models will be discussed below, wherein the polyclonality is acquired, not de novo. Bjerknes et al. (1997) have reported adenomas in FAP patients in which only a subset of the dysplastic crypts have lost the expression of APC. Do these phenotypically mixed FAP human adenomas correspond to the polyclonal Min mouse adenomas documented by lineage marking ? observed that adenomas in chimeric mice in which one component was Apc +/+ were derived only from the Min/+ component. In microdissected blue and white sectors of mixed adenomas from Ch112 and Ch113, the Apc genotype has been analysed. In most cases, each sector is Apc Min /0 (Merritt et al. 1997) . Remarkably, at least two rare somatic events have contributed to the polyclonal adenoma, in distinction to the observation of assimilative dysplasia by Bjerknes et al. (1997) . How can one understand the coincident occurrence of at least two somatic non-disjunction events within a few crypt diameters of one another ? Perhaps the events are not independent. Can mitotic non-disjunction be induced by a 918 W. F. Dove and others The intestinal epithelium and its neoplasms Phil. Trans. R. Soc. Lond. B (1998) Figure 4 . Chimerism for ROSA26 (lacZ ). Whole-mount colonic tissue from a morula fusion chimera C57BL/6 6 C57BL/6ÁROSA26/+ was histochemically stained by XGal. Control non-chimeric ROSA26/+ animals display uniform staining in all cell types of the intestinal epithelium. Negative controls (C57BL/6) show no staining.
neighbouring Apc-negative clone ? Do clastogenic`storms' pass over the developing gut ? As noted above, the neonatal crypt seems to be a favoured precursor for the adenoma; neonatal crypts have an intrinsic polyclonal architecture (Schmidt et al. 1988) .
The polyclonal structure of most, if not all, early familial adenomas can re£ect any of a broad range of mechanisms for clonal interaction. Strong interaction models posit that cellular interactions are necessary for the initiation of adenomas (¢gure 5). These models resemble the formalism of the`community e¡ect' in determinative changes of embryonic potential (Gardner 1993; Gurdon et al. 1993) , or polyclonal transdetermination within imaginal disks of Drosophila (Gehring 1967) , but require that the cooperating cells be Apc-negative somatic variants. Intermediate models involve quantitative rather than qualitative requirements for cellular interaction. For example, the ability of a nascent adenoma to grow to detectable size or to survive any purging process of the host may be enhanced by fusion with a neighbouring adenoma. Finally, passive interaction models propose that only a limited region within the intestinal epithelium of an animal can develop adenomas, enhancing the probability of fusion (see Novelli et al. 1996, footnote 25) . A simple mathematical representation of the spatially random fusion model posits that pre-adenomas form by a homogeneous Poisson process and fuse if they are su¤ciently close (M. A. Newton, unpublished data). Approximations derived from this model lead to a likelihood function for a parameter governing the expected number of preadenomas in a particular region, involving only the counts of pure and mixed tumours. Linking this information with the dimensions of the intestinal regions, it is calculated that the mixed tumour counts in the small intestine of chimeras Ch112 and Ch113 do not rule out random fusion. However, for the colons of these two chimeric Min mice, the fusion model would require a spatial restriction of colonic adenomas to 20% of the available tissue. It remains unstated what biological factor would spatially restrict adenoma formation in this passive model.
Depending upon the strength of the clonal interaction that explains the polyclonal structures of most, if not all, familial intestinal adenomas, we must re-evaluate the process of sporadic cancer in this tissue. If adenoma formation absolutely requires cooperation between a pair of initiated clones, then two initiation hits are required in the familial and four in the sporadic case (cf. Knudson 1971) . In this cooperation model, it seems plausible that promoting agents would provide the necessary community of initiated cells within a single lineage through formation of an initiated microclone (Rous & Kidd 1941) . Indeed, Ponder & Wilkinson (1986) and Gri¤ths et al. (1989) have provided strong evidence for monoclonality in chemically induced intestinal tumours in mice. The latter report is particularly persuasive in that very small patch sizes were achieved, owing to the isogenicity a¡orded by X-inactivation mosaicism. Covert polyclonality would be rare in these experiments.
Daunting experimental challenges now emerge: to determine the nature and strength of the cellular interactions that explain the polyclonal structure of early familial adenomas; and to extrapolate an understanding from the familial case to the far more prevalent sporadic case. Because chemical carcinogenesis may involve tissue damage and regeneration, we cannot reliably equate that process to sporadic neoplasia.
MODIFIERS OF THE MIN PHENOTYPE
A number of molecules are already known to interact directly with the APC/Apc polypeptide, and a number of molecular species are known to be induced in intestinal adenomas. In principle, mutations that modify the Min phenotype can occur in molecules that interact with APC/Apc either directly or indirectly. The search for these interactors began with the ¢nding that F1 hybrids generated by mating the sensitive B6-Min strain to certain other inbred mouse strains show tumour multiplicities reduced by up to an order of magnitude . By synergizing with the emergent dense genetic map of the mouse organized in the Genome Center at the Massachusetts Institute of Technology (MIT), it was possible to map a polymorphic modifying locus, Mom1 (modi¢er of Min), to a 15-centimorgan (cM) interval on mouse chromosome 4 (Dietrich et al. 1993) . To study Mom1 in the absence of other polymorphic modi¢er alleles carried by Min-resistant inbred strains, a congenic derivative of C57BL/6 was established, heterozygous for a 30-cM region containing the resistance allele of strain AKR (Gould et al. 1996a) .
With this`puri¢ed' genetic material, it was possible to obtain contemporaneous parallel sets of progeny each carrying the Apc Min allele but di¡ering in the Mom1 region. The alleles at the Mom1 locus control the net growth rate of Min-induced adenomas semidominantly. Tumour multiplicity also shows a semidominant response to the alleles of Mom1. The semidominance prevented knowing which Mom1 allele is active: resistance, sensitivity, or both.
A further re¢nement of the map location of Mom1 was carried out by identifying animals carrying chromosomes recombinant within the 30-cM congenic substitution and then phenotyping a set of testcross progeny carrying the recombinant chromosome. This demanding process delimited the Mom1 locus to a 3-cM interval (Gould et al. 1996b) .
It is almost prohibitive to identify at molecular resolution a locus whose phenotype is only quantitative (Falconer & Mackay 1996) . Recombinants must be phenotyped by establishing populations of animals. The di¤culty is compounded for polymorphic determinants,
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Phil. Trans. R. Soc. Lond. B (1998) Figure 5 . Is polyclonality of intestinal adenomas necessary? The extreme model is presented in which the formation or survival of adenomas requires clonal cooperation (`polyclonal origin').
owing to the background level of polymorphic nucleotide substitution of at least one substitution per 1000 base pairs (see Dove 1987) . One can, however, explicitly test candidate genes that map within the 3-cM region to which the quantitative determinant can be feasibly mapped. One candidate, a secretory phospholipase (encoded by Pla2g2a), was suggested by MacPhee et al. (1995) , survived the 3-cM delimitation process (Gould et al. 1996b) , and therefore deserved an explicit test. A cosmid transgene carrying the entire genomic sequence for Pla2g2a was isolated by our collaborators Karen Hong and Eric Lander (MIT) and transferred into B6-Min mice (Cormier et al. 1997) . Western blots and immunohistochemistry for the secretory phospholipase indicated that the transgene was expressed throughout the small and large intestine, although the levels were much higher and the distribution more patchy in comparison with the antigen encoded by the AKR allele of Mom1.
The transgene confers a twofold reduction in tumour multiplicity on B6-Min mice, establishing that the secretory phospholipase can provide for active resistance (Cormier et al. 1997) . It is premature, however, to conclude that Pla2g2a accounts fully for Mom1. The transgene, although overexpressed, does not achieve the same level of resistance as found with two copies of the AKR allele of Mom1. Furthermore, the ¢ne-structure analysis of Gould et al. (1996b) indicated that the Mom1 locus could be subdivided into more than one factor. The full story of the e¡ects of Mom1 on the net growth rate and multiplicity of Min-induced intestinal adenomas remains to be learned.
If the e¡ect of Mom1 involves active resistance mediated by a secretory phospholipase, does it act as a cell-autonomous negative regulator of the intestinal adenoma, that is, as a classical`tumour suppressor gene'?
Two tests for cell-autonomous action of the resistance allele of Mom1 have been carried out: chimeras generated by grafting foetal intestine from Mom1-sensitive donors to Mom1-resistant hosts ; and chimeras generated by morula fusion, in which the Mom1-resistance allele is introduced either in the same lineage as the Min mutation, or in a separate lineage . In each case, the Min phenotype matched that of the Apc Min /+ component of the chimera; no e¡ect of the Mom1-resistance allele could be detected when that allele was carried by the Apc wild-type component of the chimera. Note that this test for cell autonomy cannot detect intercellular action between di¡erent cells lying within the same crypt lineage. Because the adult crypt is monoclonal, all its derivatives belong to the same lineage. The secretory phospholipase seems to be expressed at least in the Paneth cell compartment of the small intestinal crypts and could di¡use from that source to a¡ect the behaviour of proliferative cells within the same crypt.
Two strategic points need to be recognized in these chimeric analyses of cell-autonomous versus intercellular gene action. First, the interpretation of these experiments becomes ambiguous if the components of the chimera di¡er by more than one gene a¡ecting the phenotype. In plausible situations, autonomy for one factor will obscure non-autonomy for a second (¢gure 6). A second strategic consideration, raised above in respect to the Paneth cell, indicates that the resolution to which cell autonomy can be assessed depends upon the clonal architecture of the tissue in question. In an extreme situation in which an entire tissue emerges from one somatic clone, one clearly cannot judge whether there is non-autonomous gene action between di¡erent cells within that tissue.
Mom1 fails to show one hallmark of a cell-autonomous negative regulator of neoplasia: loss of heterozygosity within tumours. Min-induced tumours in Mom1 heterozygotes remain heterozygous over the Mom1 region ) and in particular for Pla2g2a (Gould et al. 1996b) . This genetic behaviour of a non-autonomous negative regulator of neoplasia can be classi¢ed as maintenance of heterozygosity (MOH). This observation is consistent with expression of the secretory phospholipase from the Paneth cell .
Finding that a secretory phospholipase can act as an active resistance factor, controlling the size and multiplicity of Min-induced adenomas, indicates that in some way lipid signalling positively regulates a biological process that limits the adenoma. Conceivable candidate biological processes include migration from the proliferative niche of the tumour, di¡erentiation into post-mitotic derivatives, or position-dependent apoptosis. Super¢cially at least, these possibilities are distinct from those that underlie the e¡ects of mutations in the inducible cyclooxygenase gene Cox2 (Oshima et al. 1996) . Here, a loss of function results in a strong reduction in adenoma size and multiplicity, as if Cox2 were a positive growth regulator involved in the metabolic maintenance of the adenoma through prostaglandin biosynthesis. Thus, two contrasting roles can be imagined for the e¡ects of lipid metabolism in general on adenoma formation or maintenance. Perhaps, the secretory phospholipase does not operate through prostaglandin biosynthesis.
Does the study of Mom1 and the secretory phospholipase in the Min mouse bear on human colon cancer, familial or sporadic ? Several investigators have failed to ¢nd an association of the allelic status of the human homologue PLA2G2A with the severity of familial colon cancer or the risk for sporadic colon cancer. Furthermore, somatic mutations in this gene have not yet been found in human colon cancers (Riggins et al. 1995; Spirio et al. 1996; Tomlinson et al. 1996a,b) . The failure to ¢nd mutations in tumour material is explained if the e¡ects of the secretory phospholipase are non-autonomous to the tumour. The failure to ¢nd epidemiological associations between familial disease severity and the allelic status of PLA2G2A may re£ect the fact that severely a¡ected mutant alleles of this gene have not yet been found in the human population, in contrast to the frameshift allele of the sensitive C57BL/6 mouse strain. Thus, the relevance of the secretory phospholipase to human colon cancer is unresolved.
As a general proposition, the di¤culties in identifying quantitative modi¢er loci in the human may remain largely insuperable if one works solely with human family data and performs genomic scanning for association of genotype and phenotype. Crucially, one is also not con¢dent a priori that the phenotyping of the available human families has the same objective quality as that of a closed population of heterozygous congenic mice segregating for a single genetic factor. The clinical diagnosis may emphasize the status of the most advanced tumour in an individual rather than the overall adenoma phenotype (see Tomlinson et al. 1996a) . Further, the contribution of environmental variation to the phenotypic variation in human populations may overwhelm subtle quantitative e¡ects of modifying alleles. Thus, in a genomic scan for modifying alleles, the statistical power to map a genetic modi¢er may be inadequate to overcome the environmental variation and the imprecision of the phenotyping. It would seem that the best available strategy is to test speci¢c candidate loci for phenotypic e¡ect within the available human families. One source for candidate loci is the set of human homologues of any modi¢er loci identi¢ed for the cognate process in the mouse. However, one is not assured that equally informative alleles are available in the two species. Tomlinson et al. (1996a,b) have found an association of an index of disease severity in FAP families with the 1p35^36 region in the human genome surrounding the PLA2G2A locus, although, ironically, not with alleles of the secretory phospholipase.
CONCLUDING REMARKS
An entre¨e into the study of the intestinal epithelium is provided by the Min strain of the mouse, a familiar intestinal cancer model. Beyond identifying the highly penetrant germline lesion that leads to this cancer, we have been able to identify a modifying locus, Mom1, that alters the expressivity of the Min mutation. The strain AKR contains alleles that modify the phenotype even further, yet retain the common theme: Apc function must be attenuated or lost in intestinal adenomas. The Mom1 locus constitutes the beginning of an exploration of the genetic network that impinges on Apc and intestinal cancer. The general use of the ROSA26 cell lineage marker permits analysis of the clonality of the neoplastic transitions and the range of action of any genetic modi¢er.
The cellular interactions within epithelia re£ect a network of genetic interactions. The cellular/genetic interactions and the overall dynamics of the network can best be approached by ¢nding single genetic di¡erences that a¡ect the system, identifying the molecule involved and then analysing the mode of action by chimerism and by cellular biochemistry. The analysis of an entire system will bring human genetics into a new level of dialogue with the biology of the human, moving beyond the search for`disease-causing genes'.
The geneticist's response to the challenge lodged by Garrod in his valedictory 1927 lecture (table 1) is to start with a population of individuals at high risk to a disease and to ¢nd mutant alleles that either suppress or enhance that disease. We believe that Mom1 has no strongly detrimental e¡ects of its own, because the C57BL/6 mouse is healthy although homozygous for a frameshift mutation in the secretory phospholipase. In the presence of the Min mutation, however, the status of the Mom1 locus makes a signi¢cant di¡erence, apparently by conferring active resistance. Modifying activity on a primary disease phenotype is one way to discover alleles with only favourable e¡ects.
The APC/Apc gene is broadly expressed in the mammal. Indeed, both human and mouse families heterozygous for APC/Apc mutations develop extracolonic lesions, including desmoid ¢bromas. The incidence of these extracolonic lesions depends on speci¢c modi¢er loci. De¢ciency for p53 greatly enhances desmoid formation in Min mice, but has little e¡ect on the early stages of intestinal neoplasia (R. B. Halberg and W. F. Dove, unpublished data). By contrast, Mom1 does not strongly a¡ect desmoid neoplasia. Thus, the neoplastic phenotype of Min mice involves loci secondary to Apc that are speci¢c for particular tissues.
In pursuing the whole story of intestinal cancer with the laboratory mouse, there are two major needs: (i) the expansion of the search for modifying alleles; and (ii) the development of in vitro systems of analysis that recapitulate aspects of the processes that are relevant in vivo. Meeting the ¢rst need will surely enhance meeting the second, as each in vitro preparation from mutant material will provide a substrate for the study of the single missing substance. The successes in developing haematopoietic cultures that show response to the Steel and W mutations have provided a strong precedent for such a general in vivo/in vitro strategy (Dexter 1986; Dexter & Allen 1992) . Over the coming decade, investigations of the intestinal epithelium in vivo may develop a more direct line of communication with manipulations in vitro.
It will be interesting to see whether experimental investigations will bring forward an understanding of the apparent six-hit actuarial incidence curve for clinically diagnosed colon cancer in the human. Beyond epidemiology, experimental investigators will want to explore which fundamental biological lessons can be conveyed from the laboratory into the realms of prevention and therapy.
The recent work to which we refer in this overview has enjoyed several generous gifts; we thank Phil Soriano (Hutchinson Cancer Center, Seattle) for ROSA11 and ROSA26 lacZ insertions; Carol Midgley, David Lane and Peter Hall (University of Dundee) for antibodies to Apc; and Rita Mulherkar (Tata Institute, Mumbai, India) for antibodies to Pla2g2a. Our work with the Min strain was initiated with Dr Amy Moser (Wisconsin) Di¤cult as it is to detect an error of the body chemistry by its evil e¡ects, which may be long postponed, it [is] more di¤cult to detect those which are harmless or have only good e¡ects. (Garrod 1927) . . . my colleagues and I foresee decades in which mouse strains that closely simulate human disease predispositions will be used to detect protective genes. . . . It will be interesting to see what comes of this. (Dove 1995) Genetic mutation proves to be a blessing These new discoveries [that a genetic mutation can protect certain individuals from the AIDS virus] are a reminder that genetic mutations, though often deemed``defects'', can sometimes prove a blessing, conferring surprising bene¢ts on those lucky enough to inherit them. (New York Times 1996) 
